key: cord-0697752-qi967x2i authors: Alroomi, Moudhi; Rajan, Rajesh; Alsaber, Ahmad; Pan, Jiazhu; Abdullah, Mohammed; Abdelnaby, Hassan; Aboelhassan, Wael; AlNasrallah, Noor; Al‐Bader, Bader; Malhas, Haya; Ramadhan, Maryam; Hussein, Soumoud; Alotaibi, Naser; Al Saleh, Mohammad; Zhanna, Kobalava D.; Almutairi, Farah title: In‐hospital mortality in SARS‐CoV‐2 stratified by gamma‐glutamyl transferase levels date: 2022-03-09 journal: J Clin Lab Anal DOI: 10.1002/jcla.24291 sha: 2d500e11e545f6ef45c13f0bc6ab05bb4f9f273d doc_id: 697752 cord_uid: qi967x2i BACKGROUND: This study investigates in‐hospital mortality amongst patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its relation to serum levels of gamma‐glutamyl transferase (GGT). METHODS: Patients were stratified according to serum levels of gamma‐glutamyl transferase (GGT) (GGT<50 IU/L or GGT≥50 IU/L). RESULTS: A total of 802 participants were considered, amongst whom 486 had GGT<50 IU/L and a mean age of 48.1 (16.5) years, whilst 316 had GGT≥50 IU/L and a mean age of 53.8 (14.7) years. The chief sources of SARS‐CoV‐2 transmission were contact (366, 45.7%) and community (320, 40%). Most patients with GGT≥50 IU/L had either pneumonia (247, 78.2%) or acute respiratory distress syndrome (ARDS) (85, 26.9%), whilst those with GGT<50 IU/L had hypertension (141, 29%) or diabetes mellitus (DM) (147, 30.2%). Mortality was higher amongst patients with GGT≥50 IU/L (54, 17.1%) than amongst those with GGT<50 IU/L (29, 5.9%). More patients with GGT≥50 required high (83, 27.6%) or low (104, 34.6%) levels of oxygen, whereas most of those with GGT<50 had no requirement of oxygen (306, 71.2%). Multivariable logistic regression analysis indicated that GGT≥50 IU/L (odds ratio [OR]: 2.02, 95% confidence interval [CI]: 1.20–3.45, p=0.009), age (OR: 1.05, 95% CI: 1.03–1.07, p<0.001), hypertension (OR: 2.06, 95% CI: 1.19–3.63, p=0.011), methylprednisolone (OR: 2.96, 95% CI: 1.74–5.01, p<0.001) and fever (OR: 2.03, 95% CI: 1.15–3.68, p=0.016) were significant predictors of all‐cause cumulative mortality. A Cox proportional hazards regression model (B = −0.68, SE =0.24, HR =0.51, p = 0.004) showed that patients with GGT<50 IU/L had a 0.51‐times lower risk of all‐cause cumulative mortality than patients with GGT≥50 IU/L. CONCLUSION: Higher levels of serum GGT were found to be an independent predictor of in‐hospital mortality. Amongst cases of coronavirus disease , 60% of patients have deranged liver diseases. 1 Many studies have shown that 2-11% of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have an underlying liver disease. 2 In SARS-CoV-2, deranged liver function is considered a marker of the severity of the disease. [3] [4] [5] Gamma-glutamyl transferase (GGT) is considered a specific diagnostic biomarker of hepatic cholangiocytic activity. 6, 7 SARS-CoV-2-related liver injury in relation to cholangiocytic activity can be assessed by analysing GGT serum levels. 8 GGT levels are elevated in SARS-CoV-2 infection, 2 which is mostly attributed to the immune-mediated response and cytotoxicity. 9,10 2 | ME THODS This study examined 802 patients with confirmed SARS-CoV-2 infection, including both Kuwaitis and non-Kuwaitis aged 18 years or older. Patients were enrolled in this retrospective cohort study between 26 February and 8 September 2020. [ Figure 1 .] All the data were obtained from electronic medical records from two tertiary care hospitals in Kuwait: Jaber Al-Ahmed Hospital and Al Adan General Hospital. [11] [12] [13] An electronic case-record form (CRF) was used for data entry. According to the study hospital protocol, biochemistry laboratory results would usually be reported in the electronic medical records on the first days of admission. Blood samples were collected by a nurse on the same day of the report. We documented this one-time point result for each study participant admitted with a confirmed COVID-19 diagnosis. Hence, the GGT results in our study reflect the baseline laboratory profile. Our study analysed GGT on admission as a predictor for COVID-19-related mortality. Other GGT-related predictors, such as those related to the treatment effect or effect of hospitalization, were beyond the scope of the study. The primary outcome measured was SARS-CoV-2-related mortality as defined by ICD-10 code U07. 1 with GGT<50 IU/L had a 0.51-times lower risk of all-cause cumulative mortality than patients with GGT≥50 IU/L. Higher levels of serum GGT were found to be an independent predictor of in-hospital mortality. COVID-19, gamma-glutamyl transferase, in-hospital mortality, SARS-CoV-2 'none', 'low', or 'high'. Patients who were on oxygen via a nasal cannula or a nonrebreather mask were classified as the low requirement category. Those who required extracorporeal membrane oxygenation (ECMO), invasive ventilation, noninvasive ventilation or highflow oxygen were grouped in the high requirement category. Descriptive statistics were used to summarize the data in the form of the frequency, percentage, mean ± standard deviation (SD) and median ±interquartile range (IQR). Pearson's χ2 test was performed to determine the factors associated with the GGT cohorts The baseline characteristics of the COVID-19 patients are shown in Table 1 . A total of 802 hospitalized patients were enrolled in the study and stratified based on GGT<50 IU/L and GGT≥50 IU/L. The ratio of females to males was 297:504. The average age of patients with GGT≥50 IU/L was 53.8 ± 14.7 years, opposed to that of patients with GGT <50 IU/L (48.1 ± 16.5 years). Our study is one of the first to concentrate on in-hospital mortality in SARS-CoV-2 in specific relation to serum GGT levels. The main finding of our study is that higher levels of serum GGT (≥50 IU/L) were an independent predictor of in-hospital mortality. Other than serum GGT levels, age, hypertension, methylprednisolone use and fever were found to be predictors of in-hospital mortality. There Abnormal GGT levels during admission predict worse outcomes in critically ill SARS-CoV-2 patients. 15, 16 Higher levels of GGT were associated with elderly patients. 17 The severity of SARS-CoV-2 has been observed to be higher in elderly men who have elevated GGT levels. 18 Worse SARS-CoV-2-related prognoses and outcomes have been reported in a male cohort with elevated GGT. 19 Elevated GGT and CRP have strong interactions with the outcomes of SARS-CoV-2. 20 Elevated GGT is mostly seen in association with elevated ALP and AST in SARS-CoV-2. 21 ICU admissions have been seen more often in SARS-CoV-2 patients with elevated serum GGT levels. 18 Higher mortality has been reported in patients who were previously known to have had liver disease. 22, 23 One-month mortality was seen to be higher in SARS- This study demonstrated that serum GGT≥50 IU/L is an independent predictor of in-hospital mortality in SARS-CoV-2 patients. The incidence of ICU admission was higher with elevated serum GGT levels. More prospective studies are required to better understand the role of serum GGT levels in predicting in-hospital mortality in COVID-19. 'The authors would like to thank Dr Danah Alothman, Dr Mohamed Elmetwalli Ghazi and Dr Dhari Alown for their support in manuscript review'. No conflict of interest to disclose for any author on this manuscript. MAR designed the study. MAR and RR participated in data analysis and wrote the manuscript. AAS and JP performed the statistical analysis and reviewed the manuscript. The remaining authors collected the data. All authors had access to the data and took responsibility for the integrity and accuracy of data analysis. All authors have read and approved the manuscript. The authors thank Dr Danah Alothman, Dr Mohamed Elmetwalli Ghazi, and Dr Dhari Alown for their support in manuscript review. The requirement for patient consent was waived because of the retrospective observational study design. No material from other sources was included in this study. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions. https://orcid.org/0000-0001-6907-011X Rajesh Rajan https://orcid.org/0000-0002-0249-0440 Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U Liver injury in COVID-19: management and challenges COVID-19: Abnormal liver function tests Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study Clinical Features of COVID-19-Related Liver Functional Abnormality Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue Gamma glutamyl transferase Evaluation of gamma glutamyltransferase (GGT) levels in COVID-19: a retrospective analysis in tertiary care centre SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study In-hospital mortality in SARS-CoV-2 stratified by hemoglobin levels: a retrospective study In-hospital mortality in SARS-CoV-2 stratified by serum 25-hydroxy-vitamin D levels: a retrospective study Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients Tutorial: survival estimation for Cox regression models with time-varying coefficients using SAS and R Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study Derangements of Liver enzymes in Covid-19 positive patients of Pakistan: a retrospective comparative analysis with other populations Influence of age and body mass index on gamma-glutamyltransferase activity: a 15-year follow-up evaluation in a community sample Liver injury during highly pathogenic human coronavirus infections Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study γ-Glutamyltransferase elevations are frequent in patients with COVID-19: a clinical epidemiologic study Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study High rates of 30-day mortality in patients with cirrhosis and COVID-19 SARS-CoV-2 Infection and the Liver γ-Glutamyl transferase as a risk factor for all-cause or cardiovascular disease mortality among 5912 ischemic strokes Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China In-hospital mortality in SARS-CoV-2 stratified by gammaglutamyl transferase levels